Home/Biosimilar Atlas/Companies/Pfizer

Pfizer

Biosimilar developer, United States. 7 development products across 7 molecules: adalimumab, bevacizumab, filgrastim, infliximab, pegfilgrastim, rituximab, trastuzumab.

First approval in the Atlas: Jun 2010, Nivestim, filgrastim (EMA)
FDAproducts approved7
EMAproducts approved7
MHRAproducts approved5
PMDAproducts approved4
HCproducts approved7
CDSCOproducts approved0
EDEproducts registered4
Connections
7molecules7products6 of 7markets0candidates in trials8companies on the same molecules

About Pfizer

Pfizer's biosimilar range is built around three cancer antibodies, rituximab, trastuzumab and bevacizumab, sold as Ruxience, Trazimera and Zirabev, and the growth factors filgrastim and pegfilgrastim from its Hospira unit. Seven molecules are approved in the United States, Europe and Canada, four in Japan under Pfizer's own name, and four registered in the UAE. Pfizer also sells Celltrion's infliximab in the United States and India, and never launched its own.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabAbrilada / Amsparity PF-06410293Nov 2019Feb 2020··Jan 2021··3/7
BevacizumabZirabev PF-06439535Jun 2019Feb 2019MHRAJun 2019Jun 2019·Dec 20206/7
FilgrastimNivestym / Nivestim PF-06881893Jul 2018Jun 2010MHRA·Apr 2020··4/7
InfliximabIxifi / Zessly PF-06438179 (GP1111)Dec 2017May 2018MHRAJul 2018Dec 2021··5/7
PegfilgrastimNyvepria PF-06881894Jun 2020Nov 2020··Oct 2020·May 20244/7
RituximabRuxience PF-05280586Jul 2019Apr 2020MHRASep 2019May 2020·Feb 20216/7
TrastuzumabTrazimera PF-05280014Mar 2019Jul 2018MHRASep 2018Aug 2019·Apr 20206/7

Month shown is the first approval or registration of that product in that market.

Also holds or markets

Products developed by another company for which Pfizer is the licence holder or applicant in one or more markets.

MoleculeBrandMarketHolder or applicantApprovedDeveloper
Epoetin alfa and zetaRetacritEMAPfizer Europe MA EEIGDec 2007Norbitec (Stada and Hospira)
Epoetin alfa and zetaRetacritFDAHospira Inc., a Pfizer CompanyMay 2018Norbitec (Stada and Hospira)
InfliximabInflectraEMAPfizer Europe MA EEIGSep 2013Celltrion
InfliximabPfizer (INN only)CDSCOPfizer LimitedSep 2021Celltrion

In development

ClinicalTrials.gov lists four comparative trials sponsored by Pfizer for three molecules: bevacizumab, filgrastim, pegfilgrastim. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
BevacizumabPF-06439535PfizerAvastinPhase 1Comparative PKCompletedJan 2014Aug 2014ZirabevNCT02031991
BevacizumabPF-06439535PfizerAvastin (as licensed reference)Phase 1Comparative PKWithdrawnJan 2021Jul 2021ZirabevNCT04126044
FilgrastimFilgrastim HospiraPfizerNeupogenPhase 1Comparative PKCompletedOct 2016Jan 2017Nivestym / NivestimNCT02923791
PegfilgrastimPF-06881894PfizerNeulastaPhase 1Comparative PKCompletedOct 2017Jul 2018NyvepriaNCT03273842

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Pfizer, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AmgenFive shared molecules: adalimumab, bevacizumab, infliximab, rituximab, trastuzumab8 molecules in its portfolioCelltrionFive shared molecules: adalimumab, bevacizumab, infliximab, rituximab, trastuzumab10 molecules in its portfolioIntas PharmaceuticalsFive shared molecules: bevacizumab, filgrastim, pegfilgrastim, rituximab, trastuzumab12 molecules in its portfolioReliance Life SciencesFive shared molecules: adalimumab, bevacizumab, infliximab, rituximab, trastuzumab14 molecules in its portfolioCuraTeQ BiologicsFour shared molecules: bevacizumab, filgrastim, pegfilgrastim, trastuzumab4 molecules in its portfolioDr. Reddy's LaboratoriesFour shared molecules: bevacizumab, pegfilgrastim, rituximab, trastuzumab6 molecules in its portfolioSamsung BioepisFour shared molecules: adalimumab, bevacizumab, infliximab, trastuzumab10 molecules in its portfolioSandozFour shared molecules: adalimumab, filgrastim, pegfilgrastim, rituximab10 molecules in its portfolio

Chronology

Compare Pfizer with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.